PALI insider filings
PALISADE BIO, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-21. Screen PALI transaction legs live →
Insider transaction summary — last 90 days
2026-07-29 to 2026-10-27, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing by 1 insider — 20,000 shares, $28,800 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: purchase of 10,000 shares @ $1.46 ($14,600) by Williams Donald Allen, filed 2026-10-05.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Williams Donald Allen — Director | 1 | 2 legs · 20,000 sh · $28,800 | — | — |
| Finley John David — CEO CFO, Director | 2 | — | — | 6 |
| Jones Mitchell Lawrence — See Remarks | 1 | — | — | 4 |
| Capers Julien E. — See Remarks | 2 | — | — | 1 |
Recent insider filings — PALISADE BIO, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-21 | 4 | Capers Julien E. — See Remarks | Grant/award (A): 787,300 | EDGAR |
| 2026-10-21 | 3 | Capers Julien E. — See Remarks | Holdings only — no transactions reported | EDGAR |
| 2026-10-07 | 4 | Finley John David — CEO CFO, Director | Option exercise (M): 3,227,384 · Tax withholding (F): 1,411,982 @ $1.49 · Option exercise (M): 3,059,800 (derivative) @ $0 · Option exercise (M): 167,584 (derivative) @ $0 | EDGAR |
| 2026-10-07 | 4 | Jones Mitchell Lawrence — See Remarks | Option exercise (M): 2,620,850 · Tax withholding (F): 1,031,102 @ $1.49 · Option exercise (M): 2,555,266 (derivative) @ $0 · Option exercise (M): 65,584 (derivative) @ $0 | EDGAR |
| 2026-10-05 | 4 | Williams Donald Allen — Director | Purchase (P): 10,000 @ $1.42 · Purchase (P): 10,000 @ $1.46 | EDGAR |
| 2026-08-21 | 4 | Finley John David — CEO, CFO, Director | Gift (G): 88,400 @ $0 · Gift (G): 88,400 @ $0 | EDGAR |
| 2026-07-10 | 4 | Baltera Robert Jr. — Director | Purchase (P): 20,000 @ $1.99 · Purchase (P): 25,000 @ $1.96 | EDGAR |
| 2026-07-08 | 4 | Baltera Robert Jr. — Director | Purchase (P): 20,000 @ $2.05 · Purchase (P): 30,000 @ $2.03 | EDGAR |
| 2026-07-08 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Option exercise (M): 131,167 · Sale (S): 51,880 @ $2.05 · Option exercise (M): 131,167 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Finley John David — CEO, CFO, Director | Option exercise (M): 335,167 · Sale (S): 146,798 @ $2.07 · Option exercise (M): 133 @ $0.70 · Option exercise (M): 335,167 (derivative) @ $0 · Option exercise (M): 133 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Baltera Robert Jr. — Director | Purchase (P): 20,000 @ $1.98 · Purchase (P): 10,000 @ $1.98 | EDGAR |
| 2026-06-18 | 4 | Baltera Robert Jr. — Director | Grant/award (A): 336,904 | EDGAR |
| 2026-06-12 | 4 | Wei Binxian — Director | Grant/award (A): 592,300 · Option exercise (M): 20,200 · Option exercise (M): 20,200 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Williams Donald Allen — Director | Grant/award (A): 1,498,900 · Option exercise (M): 60,666 · Option exercise (M): 60,666 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Chuang Emil — Director | Grant/award (A): 592,300 · Option exercise (M): 20,200 · Option exercise (M): 20,200 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Zwick Jordan Michael — Director | Grant/award (A): 336,904 | EDGAR |
| 2026-02-13 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Option exercise (M): 8,000 · Sale (S): 1,989 @ $1.75 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Finley John David — CEO, CFO, Director | Option exercise (M): 13,333 · Sale (S): 3,896 @ $1.75 · Option exercise (M): 13,333 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Grant/award (A): 787,000 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Finley John David — CEO, CFO, Director | Grant/award (A): 2,011,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Williams Donald Allen — Director | Purchase (P): 5,000 @ $1.67 | EDGAR |
| 2026-01-13 | 4 | Williams Donald Allen — Director | Purchase (P): 5,000 @ $1.88 | EDGAR |
| 2025-11-06 | 4/A | Williams Donald Allen — Director | Grant/award (A): 182,000 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4/A | Wei Binxian — Director | Grant/award (A): 60,600 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4/A | Chuang Emil — Director | Grant/award (A): 60,600 (derivative) @ $0 | EDGAR |
| 2025-10-08 | 4 | Williams Donald Allen — Director | Grant/award (A): 1,538,700 (derivative) @ $0 | EDGAR |
| 2025-10-08 | 4 | Wei Binxian — Director | Grant/award (A): 510,700 (derivative) @ $0 | EDGAR |
| 2025-10-08 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Grant/award (A): 7,665,800 (derivative) @ $0 | EDGAR |
| 2025-10-08 | 4 | Finley John David — CEO, CFO, Director | Grant/award (A): 9,179,400 (derivative) @ $0 | EDGAR |
| 2025-10-08 | 4 | Chuang Emil — Director | Grant/award (A): 510,700 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Williams Donald Allen — Director | Grant/award (A): 64,400 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Wei Binxian — Director | Grant/award (A): 18,800 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Grant/award (A): 289,000 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Finley John David — CEO, CFO, Director | Grant/award (A): 323,400 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Chuang Emil — Director | Grant/award (A): 18,800 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | Chuang Emil — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Grant/award (A): 29,000 (derivative) @ $0 · Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Finley John David — CEO, CFO, Director | Grant/award (A): 47,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Wei Binxian — Director | Option exercise (M): 388 @ $0 | EDGAR |
| 2024-11-22 | 4 | Williams Donald Allen — Director | Option exercise (M): 388 @ $0 | EDGAR |
| 2024-07-15 | 4 | Wei Binxian — Director | Grant/award (A): 2,100 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Fischbein Margery B. — Director | Grant/award (A): 2,100 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Williams Donald Allen — Director | Grant/award (A): 2,100 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Wei Binxian — Director | Option exercise (M): 465 @ $0 | EDGAR |
| 2024-06-12 | 4 | Williams Donald Allen — Director | Option exercise (M): 340 @ $0 | EDGAR |
| 2024-05-30 | 4 | Jones Mitchell Lawrence — Chief Medical Officer | Option exercise (M): 2,735 @ $0 · Tax withholding (F): 810 @ $4.76 · Option exercise (M): 1,555 @ $0 · Tax withholding (F): 461 @ $4.76 · Option exercise (M): 2,735 (derivative) · Option exercise (M): 1,555 (derivative) | EDGAR |
| 2024-05-30 | 4 | Finley John David — CEO, CFO, Director, Director | Option exercise (M): 1,622 @ $0 · Tax withholding (F): 467 @ $4.76 · Option exercise (M): 3,335 @ $0 · Tax withholding (F): 959 @ $4.76 · Option exercise (M): 2,111 @ $0 · Tax withholding (F): 607 @ $4.76 · +3 more | EDGAR |
| 2024-05-29 | 4 | Williams Donald Allen — Director | Purchase (P): 1,000 @ $4.86 | EDGAR |
| 2024-05-28 | 4 | Finley John David — CEO, CFO, Director, Director | Purchase (P): 1,000 @ $4.81 | EDGAR |
| 2024-05-22 | 4 | Finley John David — CEO, CFO, Director, Director | Grant/award (A): 666 @ $4.97 | EDGAR |
Recent 8-K events — PALISADE BIO, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-04 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-10-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-10-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-10-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-26 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PALI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs